Summary

Systemic onset JIA (SoJIA) is unique in terms of its clinical manifestations, prognosis, and response to therapy. This article presents results of a multicenter randomized double-blind trial [NCT00339157] conducted in patients with SoJIA where the objectives were to investigate immunological mechanisms underlying the disease and assess the effect of anakinra at a transcriptional level using patient blood transcriptional profiles.